北京中医药2025，Vol.44Issue(8)：981-985,5.DOI:10.16025/j.1674-1307.2025.08.007
荆花胃康胶丸补救治疗幽门螺杆菌感染的多中心随访研究
Multicenter follow-up study on the salvage treatment of Helicobacter pylori infection with Jinghua Weikang Capsules
摘要
Abstract
Objective To observe the effect of Jinghua Weikang Capsules in salvage therapy for Helicobacter pylori(Hp)infection.Methods A total of 488 Hp infected patients who underwent salvage therapy between January 2019 and December 2023 at six hospitals were selected.The patients were randomly divided into four groups using block randomization:the bismuth quadruple therapy control group,Jinghua Weikang Group A,Jinghua Weikang Group B,and Jinghua Weikang Group C.The control group received triple therapy[rabeprazole(20 mg per dose,twice daily)+amoxicillin(1 000 mg per dose,twice daily)+furazolidone(100 mg per dose,twice daily)]combined with bismuth potassium citrate(220 mg per dose,twice daily)for 14 days.Groups A,B,and C received the same triple therapy(14 days)combined with Jinghua Weikang Capsules(240 mg per dose,twice daily)for 14,28,and 10 days,respectively.Symptom scores were compared before treatment and at 3 and 6 months after discontinuation.The 13C-urea breath test was repeated 1 year after the final treatment to calculate recurrence rates.Efficacy across groups was analyzed.Results At 3 and 6 months after treatment,the total symptom scores in all groups were lower compared to baseline(P<0.05).Groups A and B showed reduced scores for loose stools,abdominal distension,and belching compared to baseline and the bismuth quadruple therapy control group(P<0.05).At 6 months,total symptom scores in Groups A,B,and C were lower than in the control group(P<0.05).No significant difference in recurrence rates was observed among groups(P<0.05).The overall effective rates in Groups A,B,and C were higher than in the control group(P<0.05).Conclusion Jinghua Weikang Capsules combined with furazolidone-based triple therapy(with varying durations and regimens)demonstrated slightly lower recurrence rates and more sustained symptom improvement compared to bismuth quadruple therapy.关键词
荆花胃康胶丸/补救治疗/幽门螺杆菌感染/多中心随访研究/中西医结合Key words
Jinghua Weikang Capsules/salvage therapy/Helicobacter pylori infection/multicenter follow-up study/integrated traditional Chinese and Western medicine引用本文复制引用
沈姝玥,史宗明,张学智,叶晖,王自成,杨尧,杨闪闪,曹峻文,米尔阿依·穆合塔尔,叶苏漫,肖惠霞..荆花胃康胶丸补救治疗幽门螺杆菌感染的多中心随访研究[J].北京中医药,2025,44(8):981-985,5.基金项目
首都卫生发展科研专项重点攻关项目(首发2018-1-4072) （首发2018-1-4072）
国家中医药管理局中医药传承与创新"百千万"人才工程岐黄学者(国中医药人教函[2022]6号) （国中医药人教函[2022]6号）
北京大学第一医院青年临床研究专项(2022CR107) （2022CR107）
